REGN5713

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Allergic RhinitisAllergySeasonal Allergic RhinitisAllergic ConjunctivitisEye Allergy

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

1

Asmanex Hfa

PPerrigo Company

Phase 3

52

Comparator: Statins

Merck & Co.

Phase 3

23

Bepreve

BBausch Health Americas, Inc.

Phase 3

24

REGN5713

Regeneron

Phase 3

15

Allegra-D

Pfizer

Phase 3

36

Ciclesonide HFA

Sumitomo Pharma America, Inc.

Phase 3

37

Asmanex

Novartis

Preclinical

128

HL151

HHanlim Pharm. Co., Ltd.

Phase 3

19

Veramyst

GSK

Preclinical

1010

Singulair

AstraZeneca

Preclinical

5Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Allergy1 trial

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Completed·Regeneron·Phase 3·NCT06602739·54 enrolled

Seasonal Allergic Rhinitis1 trial

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Completed·Regeneron·Phase 3·NCT04709575·353 enrolled

Allergic Rhinitis1 trial

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Completed·Regeneron·Phase 2·NCT05430919·217 enrolled

Allergic Conjunctivitis1 trial

A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Bet v 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Birch Pollen Allergy

Recruiting·Regeneron·Phase 3·NCT07309432·350 enrolled

Details

Drug Info

Related News